文献速递消化道肿瘤放疗放疗物理与技术

NBTXR3——首创放疗增强剂用于胰腺导管腺癌:首例患者经验报告

NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience.
PubMed 文献 · Clin Transl Radiat Oncol · 2022-01-11

本文报告首例接受NBTXR3(功能化氧化铪纳米颗粒放疗增强剂)治疗的不可切除局部晚期胰腺导管腺癌患者。66岁男性经内镜局部注射NBTXR3后12天开始IMRT 45 Gy/15次,治疗期间影像显示肿瘤内NBTXR3保留,初次随访病灶影像稳定且无治疗相关毒性。结论认为该局部内镜递送NBTXR3联合放疗的方案对不适合手术的胰腺癌患者初步可行。

要点

  • 首例不可切除局部晚期胰腺导管腺癌患者经内镜局部注射NBTXR3后接受IMRT 45 Gy/15次。
  • 治疗期间每日CT-on-rails成像显示NBTXR3在肿瘤内保留至治疗结束。
  • 初次随访病灶影像稳定,未出现治疗相关毒性,初步显示可行性。

核心结论

  • 本报告显示,对不适合手术的胰腺癌患者,局部内镜递送NBTXR3后经放疗激活初步可行。

研究设计与样本

  • 单例患者经验报告:一名66岁男性不可切除局部晚期胰腺导管腺癌患者入组临床试验,接受内镜局部递送NBTXR3后行IMRT。

主要发现

  • 患者经内镜局部递送NBTXR3,未发生任何急性不良事件。
  • 放疗采用IMRT,总剂量45 Gy,分15次每日照射;NBTXR3注射后12天开始放疗。
  • 每日CT-on-rails成像显示NBTXR3在治疗期间保留于肿瘤内。
  • 初次随访评估时病灶影像学稳定,患者未出现治疗相关毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) remains one of the leading causes of cancer-related deaths in the world. For patients with PDAC who are not eligible for surgery, radiation therapy improves local disease control, yet safely delivering therapeutic doses of radiation remains challenging due to off-target toxicities in surrounding normal tissues. NBTXR3, a novel radioenhancer composed of functionalized hafnium oxide crystalline nanoparticles, has recently shown clinical activity in soft tissue sarcoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, and advanced solid malignancies with lung or liver metastases. Here we report the first patient with pancreatic cancer treated with NBTXR3. MATERIALS AND METHODS: A 66-year-old male with unresectable locally advanced PDAC was enrolled on our clinical trial to receive NBTXR3 activated by radiation therapy. Local endoscopic delivery of NBTXR3 was followed by intensity modulated radiation therapy (IMRT). Follow-up assessment consisted of physical examination, laboratory studies including CA19-9, and CT of the chest, abdomen, and pelvis. RESULTS: The patient received NBTXR3 by local endoscopic delivery without any acute adverse events. Radiation treatment consisted of 45 Gy in 15 daily fractions using IMRT. The patient began radiation twelve days after NBTXR3 injection. Daily CT-on-rails imaging demonstrated retention of NBTXR3 within the tumor for the duration of treatment. At initial follow-up evaluation, the lesion remained radiographically stable and the patient did not demonstrate treatment-related toxicity. CONCLUSION: This report demonstrates initial feasibility of local endoscopic delivery of NBTXR3 activated by radiation therapy for patients with pancreatic cancer who are not eligible for surgery.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Bagley AF, Ludmir EB, Maitra A, et al. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. Clin Transl Radiat Oncol. 2022. PMID: 35097226. doi:10.1016/j.ctro.2021.12.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。